232 related articles for article (PubMed ID: 33315682)
21. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
22. Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma.
Wu D; Hu Y; Wei Q; Tian C; Bian Y
Clin Nucl Med; 2018 Jun; 43(6):428-430. PubMed ID: 29561526
[TBL] [Abstract][Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
25. Metastasis From Clear Cell Renal Cell Carcinoma Mimicking Well-Differentiated Pancreatic Neuroendocrine Tumor at 18F-FDG and 68Ga-DOTATOC PET/CT.
Guglielmo P; Pesella F; Sartorello A; El Khouzai B; Berti S; Muccioli S; Gregianin M
Clin Nucl Med; 2022 Jul; 47(7):e498-e499. PubMed ID: 35675141
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance and prognostic value of preoperative
Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
29. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
30. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Imaging of Pancreatic Cancer With Liver Metastases.
Deng M; Chen Y; Cai L
Clin Nucl Med; 2021 Jul; 46(7):589-591. PubMed ID: 33630809
[TBL] [Abstract][Full Text] [Related]
31. 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer.
Civan C; Isik EG; Karadogan S; Sanli Y; Kuyumcu S
Clin Nucl Med; 2023 May; 48(5):e223-e224. PubMed ID: 36754359
[TBL] [Abstract][Full Text] [Related]
32. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
[TBL] [Abstract][Full Text] [Related]
33. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu Q; Deng M; Hu M; Liu M; Chen X; Chen Y; Cai L
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1442-1452. PubMed ID: 36609606
[TBL] [Abstract][Full Text] [Related]
34. A Rare Collecting Duct Carcinoma With Widespread Metastasis Visualized by 18F-FDG PET/CT.
Li D; Fu C; You Y; Zhang Q; Zhang X
Clin Nucl Med; 2022 Jan; 47(1):93-95. PubMed ID: 34319954
[TBL] [Abstract][Full Text] [Related]
35. Role of 18F-FDG PET/CT for detection of recurrence and metastases in renal cell carcinoma-are we underusing PET/CT?
Pereira M; Punatar CB; Singh N; Sagade SN
Diagn Interv Radiol; 2022 Sep; 28(5):498-502. PubMed ID: 36218153
[TBL] [Abstract][Full Text] [Related]
36. Solitary Contralateral Adrenal Metastasis of Renal Cell Carcinoma: 68Ga-DOTATATE PET/CT Findings.
Filizoglu N; Ozguven S
Clin Nucl Med; 2022 Jan; 47(1):e41-e42. PubMed ID: 34132679
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
38. Isolated Nasal Metastasis From Renal Cell Carcinoma 9 Years After Nephrectomy Seen on FDG PET.
Yao Y; Zuo Z; Cheng Z
Clin Nucl Med; 2020 Feb; 45(2):e110-e111. PubMed ID: 31714277
[TBL] [Abstract][Full Text] [Related]
39. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT Findings of Abdominal Leiomyosarcoma.
Güzel Y; Can C; Söğütçü N; Gündeş E; Gündoğan C
Clin Nucl Med; 2021 Dec; 46(12):e594-e597. PubMed ID: 34735413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
